Designed to mimic the natural immune function

Monoclonal antibodies are designed to mimic the function of natural antibodies.¹ All antibodies function by recognizing specific segments of molecules as foreign antigens, then targeting and neutralizing them.¹ Therapeutic mAbs are produced in laboratories from a single cell line to precisely target specific antigens with minimal impact on normal immune function.²

A broad range of potential clinical applications in animals

In veterinary medicine, mAbs have great potential for treating a number of chronic conditions.¹ Since mAbs can be selectively directed against specific targets, including cytokines and receptors on cell surfaces, they have the ability to precisely target pathogens, cancer cells and cell-signaling molecules that contribute to disease while limiting effects on the immune system.^1,2

Focusing in on IL-31, a cytokine that causes itch in dogs

Interleukin (IL)-31 is a key player in the itch cycle in dogs with atopic dermatitis.² IL-31 is a pruritogenic cytokine involved in itch signaling.² Activation of allergic inflammatory responses leads to the release of IL-31, which sends the itch signal to the brain.²

A new monoclonal antibody targets and neutralizes IL-31 to help control itch in dogs with atopic dermatitis²

A new monoclonal antibody is now being used to treat canine patients with atopic dermatitis.² Canine Atopic Dermatitis Immunotherapeutic* is an effective, safe and long-lasting injection for dogs with atopic dermatitis. It is administered monthly or as needed in the individual patient. This new treatment has received conditional licensing from the USDA and is currently being used clinically by most dermatologists and some general practice veterinarians.

Canine Atopic Dermatitis Immunotherapeutic* benefits:

		Works fast and delivers 30 days of itch relief† Injected in-office, helping ensure compliance. It begins working within one day and delivers a full month of relief.3,†

		Specifically targets the itch-causing cytokine IL-31 Anti-cIL-31 mAb specifically designed to target IL-31, a key cytokine involved in sending the itch signal to the brain.2

Safe for dogs of all ages; can be used with other medicines Can be used in dogs of any age and concurrently with many common medications, including parasiticides, antibiotics, antifungals, corticosteroids, vaccines, allergen-specific immunotherapy, antihistamines and other antipruritics, such as oclacitinib and cyclosporine.4